MedPath

Transcranial Magnetic Stimulation in Alcohol Use Disorder

Not Applicable
Completed
Conditions
Alcohol Dependence
Interventions
Device: Repetitive Transcranial Magnetic Stimulation
Registration Number
NCT02862093
Lead Sponsor
Catholic University of the Sacred Heart
Brief Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) of the dorsolateral prefrontal cortex may affect neuro-adaptations associated with alcohol use disorder (AUD), potentially influencing craving and alcohol intake.

Investigators investigated alcohol intake and dopamine transporter (DAT) availability by Single Photon Emission Computed Tomography (SPECT) in the striatum of AUD patients before and after deep rTMS.

Detailed Description

The study included AUD patients. Patients were enrolled by the alcohol addiction unit of the Internal Medicine, Gastroenterology and Hepatology Department of the Catholic University in Rome, Italy, according to the inclusion criteria. Screening collection of medical history, physical, neurological and psychiatric examinations as well as laboratory tests were performed. Moreover, patients were underwent to baseline SPECT assessment of striatal DAT availability using 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (123I-FP-CIT) as the radiotracer. Subsequently, patients were randomized in two groups (matched for gender and age) by a computer program for the REAL deep rTMS or SHAM. After weekly sessions of deep rTMS for four weeks, patients were underwent to the same clinical assessment as in the screening phase and second SPECT .

Moreover, the alcohol intake during both the four weeks prior to the enrollment and the 4 weeks of rTMS sessions were assessed through the Timeline Followback (TLFB) interview, an instrument providing a retrospective estimation of the number of drinks per drinking days, the number of drinking days, the number of abstinence days, the number of heavy drinking days and the total number of drinks. Patients were also evaluated with Alcohol Dependence Scale (ADS), Obsessive Compulsive Drinking Scale (OCDS), State-Trait Anxiety Inventory Scale (STAI Y1 and STAI Y2),Zung Self-Rating Depression Scale.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • At least two days a week of excessive alcohol consumption during the month prior to screening;
  • Ability to provide informed consent;
  • A Clinical Institute of Withdrawal Assessment in Alcohol Withdrawal score < 10;
  • Willingness to abstain from or substantially reduce alcohol consumption;
  • Permanent residence.
Exclusion Criteria
  • Clinically significant psychiatric diseases;
  • Past or current abuse or dependence on substances other than alcohol or nicotine;
  • Neurological disorders;
  • Unstable medical conditions;
  • Pacemakers, implanted metallic pumps, metal implant;
  • History of complicated withdrawal symptoms;
  • Current use of psychoactive drugs;
  • Epilepsy;
  • Current use of anticonvulsants, insulin or oral hypoglycemic agents;
  • Positive urine toxicological screening;
  • Pregnancy;
  • Participation in other clinical trial in the last 60 days;
  • Involvement in a compulsory medical treatment or pending criminal proceedings.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Deep rTMSRepetitive Transcranial Magnetic StimulationThe intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
PlaceboRepetitive Transcranial Magnetic StimulationThe sham stimulation consisted of rTMS sessions without an effective instrument operation.
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Dopamine Transporter availability in the striatum throgh Single Photon Emission Computed Tomography (SPECT)Week 4
Secondary Outcome Measures
NameTimeMethod
Change From Baseline in alcohol intakeWeek 4

Trial Locations

Locations (1)

Catholic University of Rome

🇮🇹

Rome, Rm, Italy

© Copyright 2025. All Rights Reserved by MedPath